Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov;34(11):2-30.

A Human Monoclonal Antibody Against Tumor Necrosis Factor-alpha

No authors listed

A Human Monoclonal Antibody Against Tumor Necrosis Factor-alpha

No authors listed. P T. 2009 Nov.
No abstract available

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Hand Affected by Rheumatoid Arthritis Copyright © Bart's Medical Library/Phototake Plus
FIGURE 2
FIGURE 2
GO-FORWARD Patient Disposition Through Week 24 Source: Keystone 2009. Reproduced with permission from BMJ Publishing Group Ltd.
FIGURE 3
FIGURE 3
GO-FORWARD: ACR20 Responders by Treatment Group Source: Keystone 2009. Reproduced with permission from BMJ Publishing Group Ltd.
FIGURE 4
FIGURE 4
GO-AFTER Patient Disposition Through Week 24 *Patients who had less than 20% improvement in tender and swollen joint counts were given rescue therapy. Source: Smolen 2009. Reproduced with permission.
FIGURE 5
FIGURE 5
GO-AFTER: ACR20 Responders by Treatment Group Error bars=standard error. Dashed line indicates primary endpoint of ACR20 assessment at Week 14. Source: Smolen 2009. Reproduced with permission.
FIGURE 6
FIGURE 6
GO-BEFORE Patient Disposition Through Week 24 Source: Emery 2009. Reproduced with permission from the American College of Rheumatology
FIGURE 7
FIGURE 7
Percentage of Patients Achieving ACR50 Response
FIGURE 8
FIGURE 8
GO-REVEAL Patient Disposition Through Week 24 Source: Emery 2009. Reproduced with permission.
FIGURE 9
FIGURE 9
GO-REVEAL Patients Achieving ACR20 Response through Week 24 Source: Kavanaugh 2009. Reproduced with permission.
FIGURE 10
FIGURE 10
GO-RAISE Patient Disposition Through Week 24 Source: Inman 2008. Reproduced with permission of John Wiley & Sons, Inc.
FIGURE 11
FIGURE 11
GO-RAISE Patients Achieving ASAS Responses at Weeks 14 and 24 *Numbers in cohorts changed at Week 16 due to early escape provisions in trial design. Source: Inman 2008. Reproduced with permission of John Wiley & Sons, Inc.
FIGURE 12
FIGURE 12
SmartJectTM Autoinjector Features Sources: SIMPONITM prescribing information, Centocor Ortho Biotech Inc.
FIGURE 13
FIGURE 13
SIMPONITM Prefilled Single-Dose Syringe Source: Centocor Ortho Biotech Inc.
FIGURE 14
FIGURE 14
Subcutaneous (SC) Anti-TNF Agents–, *Indicated trademarks are the registered trademarks of their respective owners. †Dosing schedule presented is not inclusive of induction dosing. This presentation is not intended to compare the relative safety, efficacy, or indications of these treatments. Please refer to each product's prescribing information for recommended dosing and administration.
See this image and copyright information in PMC

References

    1. Fauci AS, Braunwald E, Kasper DL, et al., editors. Harrison’s Principles of Internal Medicine. 17th ed. New York: McGraw-Hill; 2008.
    1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58:15–25. - PubMed
    1. Wolfe F, Cathey MA. The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol. 1991;18:1298–1306. - PubMed
    1. Pincus T, Callahan LF. Reassessment of twelve traditional paradigms concerning the diagnosis, prevalence, morbidity, and mortality of rheumatoid arthritis. Scand J Rheumatol Suppl. 1989;79:67–95. - PubMed
    1. Maetzel A, Li LC, Pencharz J, et al. The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann Rheum Dis. 2004;63:395–401. - PMC - PubMed

LinkOut - more resources